Skip to search formSkip to main contentSkip to account menu

CRLX101

Known as: Cyclodextrin-Based Polymer-Camptothecin CRLX101 
A formulation of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with to a hydrophilic, cyclodextrin-based… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

IT-101
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract 3209: CRLX101, an investigational nanoparticle-drug conjugate of camptothecin, demonstrates synergy with immunotherapy agents in preclinical models
CRLX101, an investigational nanoparticle-drug conjugate (NDC) containing the payload camptothecin, is currently being clinically… 
2016
2016
Abstract CT090: Phase II trial of the NDC CRLX101 in combination with bevacizumab in patients with platinum-resistant ovarian cancer (PROC)
Background: CRLX101 is an investigational nanoparticle-drug conjugate (NDC) with a camptothecin payload. CRLX101 is a dual… 
2015
2015
Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC).
TPS4579 Background: Up to 30% of pts. with RCC present with metastatic disease and 5-year survival among these pts. is less than… 
2015
2015
Polymeric biomaterials for cancer nanotechnology.
In 2000, President Clinton announced the U.S. Government’s National Nanotechnology Initiative to invest in nanotechnology… 
2015
2015
HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab…
4543 Background: VHL inactivation occurs in most clear cell RCCs and results in expression of the HIF hypoxia response program… 
2014
2014
Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC).
412 Background: VHL is inactivated in most clear cell RCC (ccRCC) tumors giving rise to the HIF hypoxia response program and… 
2014
2014
Phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer.
TPS3667 Background: Neoadjuvant chemoradiotherapy followed by surgical resection is the standard of care for locally advanced… 
2013
2013
Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
Purpose: Targeted nanotherapies are being developed to improve tumor drug delivery and enhance therapeutic response. Techniques… 
2011
2011
Abstract A97: Final phase 1/2a results evaluating the cyclodextrin-containing nanoparticle CRLX101 in patients with advanced solid tumor malignancies.
Introduction: Topoisomerase-1-inhibiting camptothecin (CPT) and derivatives such as irinotecan (CPT-11) and topotecan demonstrate… 
2011
2011
Abstract 1306: A Phase 1b/2a study of CRLX101, a novel nanopharmaceutical of camptothecin, in solid tumor cancer patients who have failed standard therapy
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Results from a 24-patient dose-escalation safety and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)